AlzChem Group AG

  • WKN: A2YNT3
  • ISIN: DE000A2YNT30
  • Land: Deutschland

Nachricht vom 14.01.2021 | 11:39

AlzChem Group AG: Strong result - EBITDA significantly, sales slightly above forecast for fiscal year 2020

AlzChem Group AG / Key word(s): Change in Forecast
AlzChem Group AG: Strong result - EBITDA significantly, sales slightly above forecast for fiscal year 2020

14-Jan-2021 / 11:39 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Trostberg, January 14, 2021 - After an extremely positive business performance at the end of the year, AlzChem Group AG will close fiscal year 2020 with sales slightly above and adjusted EBITDA significantly above the most recent forecast.

The company now expects to generate slightly higher consolidated sales of approximately EUR 379 million in fiscal year 2020 compared to the previous year (2019: EUR 376.1 million; last forecast: stable to slightly declining). Adjusted EBITDA will increase significantly to at least EUR 53 million (2019: EUR 50.1 million; last forecast: stable to moderately declining).

The reasons for the very positive development are the recovery of the overall markets, in particular the strong increase in demand from the pharmaceutical industry and the automotive sector.

The above figures are preliminary. The final results for fiscal year 2020 will be announced on March 19, 2021.


14-Jan-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Northern Data: "Waren zum richtigen Zeitpunkt mit dem richtigen Konzept am Markt"

Kryptowährungen, allen voran Bitcoin, sind zuletzt mit deutlichen Steigerungen wieder in den Investorenfokus gerückt. Northern Data, ein Spezialist für High Performance Computing, zählt laut eigenen Angaben zu den weltweit führenden Anbietern für Infrastruktur im Bereich Bitcoin-Mining. Wir haben mit dem Gründer und CEO Aroosh Thillainathan über die Perspektiven für Bitcoin und die Wachstumsaussichten für die Northern Data gesprochen.

News im Fokus

Merck KGaA: Merck KGaA bricht klinische Studie für bintrafusp alfa (INTR@PID Lung 037) ab

20. Januar 2021, 13:30

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

20. Januar 2021